Healthcare & Life Sciences

Graviton Bioscience Corporation

United States
Sign in to unlock

About

Graviton Bioscience Corporation is developing selective ROCK2 inhibitors, including the lead asset GV101, for treating fibrotic and autoimmune diseases such as Graft Versus Host Disease and Idiopathic Pulmonary Fibrosis.

Explore Graviton Bioscience Corporation's full profile on Brouky

Funding rounds, investor list, and risk signals — unlock with a subscription.

Sign in to unlockView pricing